Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8101 to 8115 of 8981 results

  1. Violence and aggression: short-term management in mental health, health and community settings

    Discontinued Reference number: GID-NG10397

    NICE guideline
    Discontinued

  2. Surgical site infections: prevention and treatment - Update

    Discontinued Reference number: GID-NG10374

    NICE guideline
    Discontinued

  3. Bimekizumab for treating ankylosing spondylitis ID4011

    Discontinued Reference number: GID-TA11171

    Technology appraisal guidance
    Discontinued

  4. Gantenerumab for treating early Alzheimer's disease [ID6142]

    In development Reference number: GID-TA11269 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]

    Discontinued Reference number: GID-TA10892

    Technology appraisal guidance
    Discontinued

  6. Non-invasive skin closure devices for surgical incisions (MT775)

    In development Reference number: GID-MT593 Expected publication date: TBC

    Medical technologies guidance
    In development

  7. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

    Highly specialised technologies guidance
    Discontinued

  8. Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]

    Discontinued Reference number: GID-TA10474

    Technology appraisal guidance
    Discontinued

  9. Prostate cancer (hormone refractory) - atrasentan [ID390]

    Discontinued Reference number: GID-TAG379

    Technology appraisal guidance
    Discontinued

  10. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued Reference number: GID-TAG479

    Technology appraisal guidance
    Discontinued

  11. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued Reference number: GID-TA11119

    Technology appraisal guidance
    Discontinued

  12. SILK artery reconstruction device (discontinued)

    Discontinued Reference number: GID-MT81

    Medical technologies guidance
    Discontinued

  13. Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

    Discontinued Reference number: GID-TAG411

    Technology appraisal guidance
    Discontinued

  14. Venous leg ulcers - new treatments [ID394]

    Discontinued Reference number: GID-TAG370

    Technology appraisal guidance
    Discontinued

  15. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued Reference number: GID-TAG398

    Technology appraisal guidance
    Discontinued